CELU Celularity Inc - Ordinary Shares - Class A

$CELU I’m saying bullish just because their latest filing provides a date they have to be current in order to not give Helena an additional 2 million shares. So Oct 20 is only 3 weeks away. And last time I said bullish it went up. So fuck it. I still think they should file soon though!

1/3 $CELU | Deep dive into Philip A. Barach’s background and why his presence is a major strategic catalyst for Celularity: > Barach is a Wall Street institutional heavyweight specializing in fixed income, capital restructuring, and asset management: > • Ex-Co-Founder & President at DoubleLine Capital LP ($150B+ AUM) > • Ex-Group Managing Director at TCW Group ($40B+ managed) > • Ex-Principal Fixed Income Officer at CalPERS (one of the largest pension funds in the US) > He is an elite financial architect bringing top-tier governance.

$CELU Philip A. Barach President, Co-Managing Partner Philip A. Barach, CEO and Managing Member, is the FORMER President of DoubleLine Capital LP, an LA-based money management company with over $150 billion of assets under management. Prior to founding Doubleline, Philip was a Group Managing Director at TCW Group, where he managed investment portfolios in excess of $40 billion. Previously, he served as the Principal Fixed Income Officer at CalPERS. The principals directly oversee all investment functions, including acquisition, due diligence, financing, asset management and disposition, and commit their own capital to every dea

$CELU Forward looking: New highly strategic governance team of board members, $40M cenplacel-L stockpile, Potential $300M Muse Cell Manufacturing Contract, Fontaine Vitale Launch, BioCellgraft Launch, Fountain Life Partnership, DefEYE Ocular products, Lifebank & GL partnership and I'm certain there is so much more going on behind the scenes with these new heavyweights on board. GLTA, Looking forward to watching.

$CELU horrific earnings Q1. No wonder they tried to hide it all these months. Q2 will be just as bad clearly since no significant news since then. They went from doing 9mill in revenue to 870k…

$CELU He has helped the company both financially and strategically. Looking forward to his leadership as the company prepares for massive growth.

$CELU Different company, different pitch, still no clean books. They just took a private convert that starts at $10 million, 10% a year, secured, $1.50 conversion plus warrants. 1st tranche can add a third more shares if it converts. The full facility can about double the O/S count. The “$40 million” is management’s price tag on investigational inventory, not an FDA product. The path is Florida cash pay for joints/wounds/pain, in a market that already defaults to cheaper cord and birth tissue. Fountain Life is a niche clinic, not a distribution network. This could go up as next to nobody thats buying this junk understands the company rot whats actually happening. File the the 10Q's.

$CELU predicting cash flow positive is a joke. That doesn’t mean shit for a pharma company, doesn’t mean they’ll be positive for the year. 4 years ago they also said the same shit and fast forward still under water

$CELU I’m going bullish on today. Today’s a big day. Those who know, know. I’m hopeful for premarket. After hours is possible as well though.

$CELU The board members are all incredible! Looking forward to the announcement of the 5th member.

$CELU billionaires are buying warrants at 1.50 and 2$. Your 1.30 is pretty safe. I’m going bullish because we’re 3/4 of the way to compliance. And the last two bullish posts have brought news.

$CELU You're not wrong on the raw numbers—the backward-looking financials are brutal. Total sales dropped to $3.8M (-66% YoY) with product sales down 90% to $866k. But context is everything here: that product revenue drop was largely driven by the NexGel licensing agreement, which moved the degenerative disease product line off CELU’s balance sheet. Realistically, Q2 and Q3 won't look great either while this accounting and operational shift plays out. But that is precisely why the recent top-tier board additions (Barach, Jain, etc.) are crucial. The science and products exist; what CELU lacked was commercial execution. Bringing in heavyweights is all about finding real buyers, securing distribution, and monetizing these assets. Short-term accounting noise during a structured turnaround.

$CELU closed an $11.01 million senior secured convertible note and warrant financing in its initial tranche.

$CELU same shit every quarter. Increase price by 10-20% then dilute then announce some new board members, silence regarding the actual company and its progress on anything, then late on earnings for 3-6 months. Trash leadership

$CELU The financials are headed in the right direction. All the heavy lifting is done. Time to sell stem cells!

$CELU Its clear that Hariri is getting rich famous people on his board. He's looking for money. That's not an exceptional thing what kind of decent in my opinion. Cellularity will have access to ample of funds through these individuals. The next sector after AI will be longevity and this is sitting on the front line.

$CELU Shares available to short are rising and borrow fees continue to ease down. But still in the 70's which is too much for anybody to short this. There's no upside to shorting. Hence why volume is so low on the fluff PR attached to the PIPE. Until they file 2026's 10Q's, most potential buyers, especially accredited investors, can only buy on the open market when the company is financially current. Right now, all we have is volume from FOMO hoping for a surge on a company thats pumping a speculative story, rather than a company posting facts. Could it hit $1.50? Sure. Depends on the strategy of who is buying the fluff. Are they in it for the quick dime? Or did they ignore the PIPE and think this is going to moon? To each their own. I'll load up on Puts if it keeps going up. Made a bunch on the last fluff pump from 8/27 But until they file those 10Q's this isn't going to do much. Okay, thats it for now. You are all welcome for the insight.

$CELU If they got a PIPE from an accredited investor, that buyer saw something. They saw all the numbers. The only ones who haven't the numbers are every other investor. They have the info to file the 10Q's. They are currently busy doing damage control before they are released. And the buyer seeing the numbers doesn’t mean the numbers are good. This is a distressed company's Hail Mary. Those guys jump at circumstances like this. They collect the 10%. If the company can’t pay or needs more cash, they come back for a new deal. Lower conversion price, more shares. Seen that movie a 1000 times. Look at VIVK. Perfect example. All we got was a speculative PR attached to the PIPE. That’s what FOMO is for. You can get a squeeze if they pile in. You can also get every FOMO from the late August pump, selling the second they’re whole again. Nobody’s asking why the 10-Qs still aren’t filed. There’s a reason this still trades like a story, not a business. Because its just a story.